Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics) (SCAD-INSPIRE)

April 9, 2026 updated by: Intermountain Health Care, Inc.

Genetics of Spontaneous Coronary Artery Dissection (SCAD-INSPIRE Genetics): A Substudy of the INSPIRE Registry

Spontaneous coronary artery dissection (SCAD) is a rare cause of coronary ischemia and infarction where a tear in blood vessel wall either restricts the flow of blood or the blood becomes trapped in between the layers of the vessel causing the vessel to impinge on the lumen and causing an obstruction or restriction of blood flow. The ultimate goal of this proposal is to further understand the risk factors leading to SCAD with a focus on familial and genetic causes of SCAD.

Study Overview

Status

Enrolling by invitation

Detailed Description

For this study, we will ascertain clinical data and biological samples from a cohort of SCAD patients identified using retrospective review of medical records and prospective surveillance of Intermountain patients that undergo coronary angiography. The SCAD diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by two cardiologists and a third cardiologist in case of disagreement. It is anticipated that we hope to recruit 100 SCAD patients.

Enrollment of these subjects will be done under the INSPIRE registry. The subjects will be asked to sign a consent, provide biological samples, and complete questionnaires related to SCAD as part of the INSPIRE registry.

The SCAD cases will be matched to records in the Intermountain Genealogy Registry (IGR) to allow for the identification of possible high-risk SCAD families. Risk of first and second degree relatives will also be assessed. The obtained blood samples will be processed, stored and genotyped.

Study Type

Observational

Enrollment (Estimated)

100

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

The study population will be Intermountain Healthcare patients. The case subjects will be SCAD patients and the control population for the genetics will be Intermountain angiography patients without SCAD.

Description

Inclusion Criteria:

SCAD Cases

  1. Subjects of all ages, gender, or race
  2. Subjects had coronary angiography.
  3. Subjects had suspected SCAD as based on clinical report.

Controls

  1. INSPIRE subject that had coronary angiography at Intermountain Healthcare for stable angina.
  2. Subjects had no or mild atherosclerotic heart disease at time of angiography.
  3. Age at last visit as recorded in the Intermountain EDW at least 50 years or older.
  4. Not screened as possibly having a SCAD or coronary artery dissection diagnosis.

Exclusion Criteria:

SCAD Cases

  1. Independent review of cardiac imaging and clinical presentation by three cardiologists determine the coronary angiography was not a result of SCAD.
  2. Imaging from time of coronary angiography of poor quality as to not allow for proper determination of SCAD.
  3. Inability to determine criteria as outlined above.
  4. Subjects that have had a heart transplant.
  5. Subjects that have had a bone marrow transplant.
  6. Inability or refusal of the patient and/or the patient's legally acceptable representative to provide informed consent or blood sample for any reason.
  7. Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the trial.

Controls

  1. Subjects that have a heart transplant.
  2. Subjects that have a bone marrow transplant.
  3. Subjects with any of the following diagnosis at anytime

    1. Heart failure
    2. Heart valve disease
    3. Thoracic aortic aneurysm and dissection
    4. Ehlers-Danlos syndrome
    5. Shprintzen-Goldberg syndrome
    6. Marfan syndrome
    7. Loeys-Dietz aortic aneurysm syndrome
    8. Arterial tortuosity syndrome

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Family-Based
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Spontaneous Coronary Artery Disection
The spontaneous coronary artery disection (SCAD) diagnosis will be based on independent review of clinical presentation, cardiac imaging, and angiography findings by three cardiologists. The determination will be evidence of linear luminal defect (intimal flap) detection, luminal narrowing or occlusion confirmed to be a dissection on further imaging, or by clinical judgment classifying it as definite SCAD.
Control
A set of controls will be used for genetic analysis. These controls will pulled from subjects in the INSPIRE registry that had coronary angiography at Intermountain Medical Center for stable angina and meet inclusion/exclusion criteria.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Genetic variants
Time Frame: at enrollment
To determine genetic variants among spontaneous coronary artery dissection (SCAD) patients, we will do genotyping including target sequencing and whole exome/genome sequencing on samples provided by SCAD patients. The primary focus of this sequencing will be to determine rates of variants in genes that cause cardiac-related connective tissue disorders.
at enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 17, 2016

Primary Completion (Estimated)

December 31, 2036

Study Completion (Estimated)

December 31, 2036

Study Registration Dates

First Submitted

February 4, 2019

First Submitted That Met QC Criteria

March 13, 2019

First Posted (Actual)

March 15, 2019

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spontaneous Coronary Artery Dissection

Subscribe